<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04953663</url>
  </required_header>
  <id_info>
    <org_study_id>D2020093</org_study_id>
    <nct_id>NCT04953663</nct_id>
  </id_info>
  <brief_title>Clinical Plan of Ischemic Stroke</brief_title>
  <official_title>A Multicenter, Blind, Randomized, Placebo-controlled Phase I / IIA Study to Evaluate the Safety, Tolerability, and Initial Efficacy of a Single Injection of Ischemia Tolerant Human Allogeneic Bone Marrow Mesenchymal Stem Cells in Patients With Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University Third Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stroke is the main cause of adult health damage. 20% of stroke survivors need institutional&#xD;
      care after 3 months, and up to 30% of them have severe or permanent disability. Stem cells&#xD;
      are a kind of pluripotent cells with the ability of self replication. The self-renewal and&#xD;
      differentiation characteristics of mesenchymal stem cells, as well as cytokine secretion&#xD;
      effect and immune characteristics, provide the possibility for mesenchymal stem cells to&#xD;
      treat ischemic stroke. After the infusion of mesenchymal stem cells, the secretion of soluble&#xD;
      media including growth factors and cytokines may be the main mechanism of mesenchymal stem&#xD;
      cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stroke is the main cause of adult health damage. 20% of stroke survivors need institutional&#xD;
      care after 3 months, and up to 30% of them have severe or permanent disability. Stem cells&#xD;
      are a kind of pluripotent cells with the ability of self replication. The self-renewal and&#xD;
      differentiation characteristics of mesenchymal stem cells, as well as cytokine secretion&#xD;
      effect and immune characteristics, provide the possibility for mesenchymal stem cells to&#xD;
      treat ischemic stroke. After the infusion of mesenchymal stem cells, the secretion of soluble&#xD;
      media including growth factors and cytokines may be the main mechanism of mesenchymal stem&#xD;
      cells. The main purpose of this study was to evaluate the safety and tolerance of intravenous&#xD;
      injection of ischemia tolerant human allogeneic bone marrow mesenchymal stem cells in&#xD;
      patients with ischemic stroke. The secondary objective was to evaluate the clinical efficacy&#xD;
      of ischemic tolerant human allogeneic bone marrow mesenchymal stem cells in the treatment of&#xD;
      ischemic stroke patients with neurological dysfunction.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>3 arms for phase 1, and 3 arms for pashe 2</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events and serious adverse events rate</measure>
    <time_frame>In 12 months</time_frame>
    <description>Safety and tolerability of it-hMSC treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of clinical significant changes in laboratory</measure>
    <time_frame>In 12 months</time_frame>
    <description>Safety and tolerability of it-hMSC treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of abnormal neurological physical examination results</measure>
    <time_frame>In 12 months</time_frame>
    <description>Safety and tolerability of it-hMSC treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of imaging changes</measure>
    <time_frame>In 12 months</time_frame>
    <description>Safety and tolerability of it-hMSC treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of NIHSS scores</measure>
    <time_frame>1、3、6、9、12 months after treatment</time_frame>
    <description>The improvement of neurological function was evaluated by neurological</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of BI scores</measure>
    <time_frame>1、3、6、9、12 months after treatment</time_frame>
    <description>The improvement of neurological function was evaluated by neurological</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of mRS scores</measure>
    <time_frame>1、3、6、9、12 months after treatment</time_frame>
    <description>The improvement of neurological function was evaluated by neurological</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of MMSE scores</measure>
    <time_frame>1、3、6、9、12 months after treatment</time_frame>
    <description>The improvement of neurological function was evaluated by neurological</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of GDS scores</measure>
    <time_frame>1、3、6、9、12 months after treatment</time_frame>
    <description>The improvement of neurological function was evaluated by neurological</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Low dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 × 10 ^ 6 / kg (body weight) of it-hMSC per person</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Middle dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 × 10 ^ 6 / kg (body weight) of it-hMSC per person</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 × 10 ^ 6 / kg (body weight) of it-hMSC per person</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Highest dose cell group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Highest dose of it-hMSC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sub high dose cell group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sub high dose of it-hMSC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>it-hMSC</intervention_name>
    <description>Different doses of it-hMSC</description>
    <arm_group_label>High dose group</arm_group_label>
    <arm_group_label>Highest dose cell group</arm_group_label>
    <arm_group_label>Low dose group</arm_group_label>
    <arm_group_label>Middle dose group</arm_group_label>
    <arm_group_label>Sub high dose cell group</arm_group_label>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female ≥ 18 years old;&#xD;
&#xD;
          2. The history showed that the last clinical diagnosis of ischemic stroke was more than 6&#xD;
             months;&#xD;
&#xD;
          3. The results of MRI at the first diagnosis and at the time of selection indicated that&#xD;
             there was ischemic stroke and dysfunction;&#xD;
&#xD;
          4. There was no significant improvement in neurological function or functional defect 2&#xD;
             months before the study;&#xD;
&#xD;
          5. There is serious neurological dysfunction related to the diagnosis in Article 2, which&#xD;
             leads to the subjects need the assistance of others to walk, or cannot complete the&#xD;
             general activities of daily living independently;&#xD;
&#xD;
          6. NIHSS score was 6-20;&#xD;
&#xD;
          7. The life expectancy is more than 12 months;&#xD;
&#xD;
          8. Before treatment, the patient received standard medical care for secondary prevention&#xD;
             of ischemic stroke, including but not limited to appropriate blood pressure and&#xD;
             cholesterol control measures, use of antiplatelet drugs or anticoagulants (except&#xD;
             prohibited cases);&#xD;
&#xD;
          9. Be able to understand and provide the signed informed consent, or ask the designated&#xD;
             legal guardian or spouse to make the above decision voluntarily on behalf of the&#xD;
             subjects;&#xD;
&#xD;
         10. It is reasonable to expect that patients will receive standard medical care for&#xD;
             secondary prevention of ischemic stroke and participate in safety follow-up of all&#xD;
             plans;&#xD;
&#xD;
         11. Organ function determined according to the following criteria:&#xD;
&#xD;
        Serum AST ≤ 2.5 × Upper normal limit (ULN);&#xD;
&#xD;
        Serum alanine aminotransferase (ALT) ≤ 2.5 × Normal upper limit;&#xD;
&#xD;
        Total serum bilirubin ≤ 1.5 × Normal upper limit;&#xD;
&#xD;
        In subjects without antithrombotic therapy, prothrombin time (PT) and partial thrombokinase&#xD;
        time (PTT) ≤ 1.25 × Normal upper limit;&#xD;
&#xD;
        Serum albumin ≥ 3.0g/dl;&#xD;
&#xD;
        Absolute neutrophil count (ANC) ≥ 1500/ μ L；&#xD;
&#xD;
        Platelets ≥ 150000/ μ L；&#xD;
&#xD;
        Hemoglobin ≥ 9.0g/dl;&#xD;
&#xD;
        Serum creatinine ≤ 1.5 × Normal upper limit;&#xD;
&#xD;
        Serum amylase or lipase were in normal range.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of epilepsy;&#xD;
&#xD;
          2. History of tumor;&#xD;
&#xD;
          3. History of brain tumor and brain trauma;&#xD;
&#xD;
          4. hepatitis B, five surface antigens, e antigens, e antibodies and core antibodies were&#xD;
             positive for any one, positive for hepatitis C virus antibody, positive for syphilis&#xD;
             serum antibody or HIV positive.&#xD;
&#xD;
          5. Myocardial infarction occurred within 6 months before the trial;&#xD;
&#xD;
          6. Suffering from any other medical disease with clinical significance, or with abnormal&#xD;
             mental or laboratory results, the researcher or the sponsor determines that&#xD;
             participating in the trial will bring safety risks to the subjects;&#xD;
&#xD;
          7. Imaging examination showed subarachnoid hemorrhage or intracerebral hemorrhage in the&#xD;
             past 12 months;&#xD;
&#xD;
          8. Participate in another study on the use of test drug or equipment within 3 months&#xD;
             before treatment;&#xD;
&#xD;
          9. Participated in other stem cell therapy related research;&#xD;
&#xD;
         10. History of drug or alcohol abuse in the past year;&#xD;
&#xD;
         11. Women who are known to be pregnant, breast-feeding or have a positive pregnancy test&#xD;
             (to be tested during the screening process) or plan to be pregnant during the trial;&#xD;
&#xD;
         12. Allergic to cattle and pork products.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dongsheng Fan</last_name>
      <phone>13701023871</phone>
      <email>dsfan@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 27, 2021</study_first_submitted>
  <study_first_submitted_qc>July 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2021</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

